GSK Consumer Unit Holds Promise In 2008 As Rx Division Faces Challenges
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline sees consumer health care as a major opportunity in 2008 as its pharmaceutical division faces setbacks from increased generic competition and safety concerns surrounding the diabetes drug Avandia
You may also be interested in...
Under New CEO, Glaxo Will Leverage OTCs In Emerging Markets
GlaxoSmithKline will seed its growth in emerging markets with OTC drugs and other nonprescription products, according to Chris Viehbacher, the firm's North American Pharmaceuticals division president
Under New CEO, Glaxo Will Leverage OTCs In Emerging Markets
GlaxoSmithKline will seed its growth in emerging markets with OTC drugs and other nonprescription products, according to Chris Viehbacher, the firm's North American Pharmaceuticals division president
Under New CEO, Glaxo Will Leverage OTCs In Emerging Markets
GlaxoSmithKline will seed its growth in emerging markets with OTC drugs and other nonprescription products, according to Chris Viehbacher, the firm's North American Pharmaceuticals division president